Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (DE:8C5)
FRANKFURT:8C5
Coherus Biosciences (8C5) Stock Price & Analysis
2 Followers
8C5 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.43 - €6.58
Previous Close€1.99
Volume0.00
Average Volume (3M)1.97K
Market Cap
€239.21M
Enterprise Value€340.54M
Total Cash (Recent Filing)$117.75M
Total Debt (Recent Filing)$226.89M
Price to Earnings (P/E)N/A
Beta1.32
Next Earnings
May 09, 2024EPS Estimate
-€0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding112,714,488
10 Day Avg. Volume475
30 Day Avg. Volume1,971
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-0.97
Price to Sales (P/S)0.87
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.51
Enterprise Value/Gross Profit3.47
Enterprise Value/Ebitda-1.75
Forecast
1Y Price Target
€8.85Price Target Upside343.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Coherus Biosciences News
Bulls Say, Bears Say
Bulls Say
Financial StrategyCoherus's plan to achieve cash flow positivity by 2024 underscores the company's commitment to financial discipline and an improved financial outlook.
Product PipelineGiven recent progress for early stage assets, the inclusion of CHS-144 and CHS-1000 for solid tumors into valuations reflects optimism for the company's product pipeline.
Strategic DivestitureThe completed sale of the ophthalmology franchise and the subsequent debt reduction aligns with Coherus's strategy to focus on core areas and strengthens its financial position.
Bears Say
Financial PerformanceCoherus generated total revenue of $91.5M, below the Street consensus of $96.9M.
Product PerformanceYusimry uptake remains slow due to strong competition from an entrenched brand, presenting a challenge for market penetration.
RisksRisks include regulatory and clinical challenges, competition against larger companies, and potential intellectual property issues.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
4.41% Other Institutional Investors
95.59% Public Companies and
Individual Investors
8C5 FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was €1.43 and its highest was €6.58 in the past 12 months.
What is Coherus Biosciences’s market cap?
Currently, no data Available
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is May 09, 2024 which is in 3 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Mar 13, 2024. The company reported -€0.663 earnings per share for the quarter, missing the consensus estimate of -€0.193 by -€0.469.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -€0.24.
How many shares outstanding does Coherus Biosciences have?
Currently, no data Available
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -€0.663 in its last earnings report, missing expectations of -€0.193. Following the earnings report the stock price went down -4.814%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Among the largest hedge funds holding Coherus Biosciences’s share is Woodline Partners LP. It holds Coherus Biosciences’s shares valued at 2M.
---
Coherus Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.85 (343.72% Upside)
€8.85 (343.72% Upside)
Blogger Sentiment
Bullish
DE:8C5 Sentiment 75%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.94%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
---
8C5 Earnings Call
Q4 2024
0:00 / 0:00
---
8C5 Stock 12 Months Forecast
Average Price Target
€8.85
▲(343.72% Upside)
Technical Analysis
Best Analysts Covering 8C5
1 Year
1 Year Success Rate
4/20 ratings generated profit
1 Year Average Return
-26.88%
reiterated a buy rating 22 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -26.88% per trade.
---